Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity.

Although considerable effort has been devoted to developing Grb2 SH2 domain-binding antagonists, important questions related to ligand specificity, and identification of intracellular targets remain unanswered. In order to begin addressing these issues, the design, synthesis, and evaluation of a novel biotinylated macrocycle are reported that bears biotin functionality at a C-terminal rather than the traditional N-terminal position. With a Grb2 SH2 domain-binding K(eq) value of 3.4 nM, the title macrocycle (5) is among the most potent biotinylated SH2 domain-binding ligands yet disclosed. This should be a useful tool for elucidating physiological targets of certain Grb2 SH2 domain-binding antagonists.

[1]  C. García-echeverría,et al.  Biotinylated phosphotyrosine containing peptides: A valuable tool for studies on phosphopeptide interactions with SH2 and PTB domains , 1997, Letters in Peptide Science.

[2]  R. Grubbs,et al.  Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. , 1999, Organic letters.

[3]  T. Schumacher,et al.  Specificity and affinity motifs for Grb2 SH2-ligand interactions , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Dajun Yang,et al.  Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands. , 2004, Journal of medicinal chemistry.

[5]  H. Zollinger,et al.  Stereochemistry of the σ-Complex Intermediate in Sterically Hindered Electrophilic Aromatic Substitutions. (20th communication on diazo coupling reactions)† , 1970 .

[7]  T Pawson,et al.  Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav , 1994, Molecular and cellular biology.

[8]  Z. Yao,et al.  Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions* , 2001, The Journal of Biological Chemistry.

[9]  B. Roques,et al.  Inhibitors of Ras signal transduction as antitumor agents. , 2000, Biochemical pharmacology.

[10]  T. Burke,et al.  Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. , 2000, Journal of medicinal chemistry.

[11]  Marc C Nicklaus,et al.  Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic. , 2005, Bioorganic & medicinal chemistry.

[12]  T. Burke,et al.  Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor. , 2001, Organic Letters.

[13]  P. Furet,et al.  Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. , 1998, Journal of medicinal chemistry.

[14]  M. Moran,et al.  Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.

[15]  Dajun Yang,et al.  Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems. , 2003, Journal of medicinal chemistry.

[16]  G. Milne,et al.  Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. , 1999, Journal of medicinal chemistry.

[17]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[18]  C. Vu.  Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70. , 2000, Current medicinal chemistry.

[19]  Dajun Yang,et al.  A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. , 2003, Biochemical and biophysical research communications.

[20]  M. Sporn,et al.  Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. , 2004, Journal of medicinal chemistry.

[21]  P. Furet,et al.  Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. , 2000, Current pharmaceutical design.

[22]  Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. , 2001, Current medicinal chemistry.

[23]  M. Naujokas,et al.  Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis , 2002, Oncogene.

[24]  S. Feller,et al.  High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia , 2003, Leukemia & lymphoma.

[25]  R. Sutherland,et al.  Overexpression of the Grb2 gene in human breast cancer cell lines. , 1994, Oncogene.

[26]  D. Fabbro,et al.  Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility* , 1999, The Journal of Biological Chemistry.

[27]  P. Furet,et al.  Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands. , 1997, Biochemistry.